Skip to content


The world’s first low-cost Human Papillomavirus (HPV) vaccine.

Baltimore, MD


Cohort Year: Y3 (2017)
Status: Active
HQ: Baltimore, MD

Y3 (2017) Life Sciences

PathoVax LLC is a start-up company that is based on foundational technology developed at Johns Hopkins University to advance RGVaxTM, the world’s first comprehensive HPV vaccine that aims to target all clinically relevant HPV. It is expected that such additional protection will eventually establish new standards in the $2B HPV market. PathoVax’s collaborative partnerships include well-known institutions such as the U.S. National Cancer Institute to push forward an academic phase 1 study.

PathoVax Pitch at 43North Finals 2016


Josh Wang